Back to results
US 12,454,539 B2Granted
Controlled-delivery cromakalim prodrugs
AssigneesQlaris Bio, Inc., Mayo Foundation for Medical Education and Research
InventorsThurein M. Htoo, Barbara M. Wirostko, Michael P. Fautsch, Ian Garnett, Chiara Massarenti
Life of this patent
Estimating the term…
Abstract
The present invention provides cromakalim phosphate prodrugs, compositions, and their use for the modulation of ATP-sensitive potassium (KATP) channels for therapeutic purposes.
Claims19
A compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A compound of Formula I:
- wherein X+ is a counterbalancing, pharmaceutically acceptable cation, which is selected from the group consisting of an alkali metal cation and an ammonium ion.
A compound of Formula II:
- wherein M2+ is a divalent pharmaceutically acceptable cation selected from the group consisting of an alkaline earth metal cation, a metal cation with an oxidation state of +2, and an ammonium ion with a net positive charge of two.
Dependencies are inferred from the claim text.